ROWLAND LLOYD A (General Counsel) sold 3.1% of their position (4.18K shares) of CYTOMX THERAPEUTICS, INC. on the open market
Open‑market sale worth $5.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/22/2024ACC: 0001610717-24-000434
Officer· General Counsel
Since Nov 2018
-4.18K
Net shares
Net seller
$5.1K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
11.25K acquired · 15.43K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+11.25K
Price / share
—
Trade value
—
% of position
9.1%
8/20/2024
123.73K→134.98K
Common Stock
Direct
Shares
−4.18K
Price / share
$1.23
Trade value
$5.14K
% of position
3.1%
8/20/2024
134.98K→130.80K
Total
Net shares
+7.07K
Net value
-$5.14K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/20/2024 | M · Option Exercise | +11.25K | — | — | 9.1% | 123.73K | 134.98K |
| Common Stock Direct | 8/20/2024 | S · Sale | −4.18K | $1.23 | $5.14K | 3.1% | 134.98K | 130.80K |
| Total | +7.07K | -$5.14K | ||||||
Derivative Transactions1
Performance Stock Units (PSUs)
Direct
Converts to
Common Stock
11.25K shares
Shares
−11.25K
Strike price
Held after
0.00
Exercisable
—
8/20/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Performance Stock Units (PSUs) Direct | Common Stock11.25K shares | 8/20/2024 | M · Option Exercise | −11.25K | — | 0.00 |